Cholangiocarcinoma: New Insights into Disease Pathogenesis and Biology

Infectious Disease Clinics of North America

Volumn 24, Issue 4, 2010, Pages 871-884

  Braconi, Chiara ^a   Patel, Tushar ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Biliary tract cancers; Liver cancers; Liver flukes

Indexed keywords

CISPLATIN; GEMCITABINE; INTERLEUKIN 6; URSODEOXYCHOLIC ACID;

BILE DUCT CARCINOMA; BILE DUCT STONE; BILIARY TRACT MALFORMATION; BILIARY TRACT SURGERY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SCREENING; CHRONIC HEPATITIS; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DNA DAMAGE; DRUG RESPONSE; FASCIOLIASIS; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; OXIDATIVE STRESS; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIMARY SCLEROSING CHOLANGITIS; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIRUS HEPATITIS;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CLONORCHIASIS; CLONORCHIS SINENSIS; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 77957739345     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.07.006     Document Type: Review

References (67)

1. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003, 10(4):288-291.
2. Nathan H., Aloia T.A., Vauthey J.N., et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009, 16(1):14-22.
3. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33(6):1353-1357.
4. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002, 2:10.
5. El-Serag H.B., Petersen N.J., Carter J., et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004, 126(7):1692-1699.
6. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
7. McLean L., Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 2006, 26(9):1047-1053.
8. Kim H.G., Han J., Kim M.H., et al. Prevalence of clonorchiasis in patients with gastrointestinal disease: a Korean nationwide multicenter survey. World J Gastroenterol 2009, 15(1):86-94.
9. Kim Si A. Clonorchis sinensis-specific antigen that detects active human clonorchiasis. Korean J Parasitol 1998, 36(1):37-45.
10. Hou P.C. The pathology of Clonorchis sinensis infestation of the liver. J Pathol Bacteriol 1955, 70(1):53-64.
11. Haswell-Elkins M.R., Satarug S., Tsuda M., et al. Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation in human carcinogenesis. Mutat Res 1994, 305(2):241-252.
12. Honjo S., Srivatanakul P., Sriplung H., et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, Northeast Thailand. Int J Cancer 2005, 117(5):854-860.
13. Sriamporn S., Pisani P., Pipitgool V., et al. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health 2004, 9(5):588-594.
14. Andrews R.H., Sithithaworn P., Petney T.N. Opisthorchis viverrini: an underestimated parasite in world health. Trends Parasitol 2008, 24(11):497-501.
15. Suksumek N., Leelawat K., Leelawat S., et al. TaqMan real-time PCR assay for specific detection of Opisthorchis viverrini DNA in Thai patients with hepatocellular carcinoma and cholangiocarcinoma. Exp Parasitol 2008, 119(2):217-224.
16. Thanan R., Murata M., Pinlaor S., et al. Urinary 8-oxo-7, 8-dihydro-2'-deoxyguanosine in patients with parasite infection and effect of antiparasitic drug in relation to cholangiocarcinogenesis. Cancer Epidemiol Biomarkers Prev 2008, 17(3):518-524.
17. Pinlaor S., Ma N., Hiraku Y., et al. Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7, 8-dihydro-2'-deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. Carcinogenesis 2004, 25(8):1535-1542.
18. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99(3):523-526.
19. Claessen M.M., Lutgens M.W., van Buuren H.R., et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009, 15(9):1331-1336.
20. Kitiyakara T., Chapman R.W. Chemoprevention and screening in primary sclerosing cholangitis. Postgrad Med J 2008, 84(991):228-237.
21. El-Serag H.B., Engels E.A., Landgren O., et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 2009, 49(1):116-123.
22. Kobayashi M., Ikeda K., Saitoh S., et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000, 88(11):2471-2477.
23. Chen R.F., Li Z.H., Chen J.S., et al. Zhonghua Wai Ke Za Zhi 2005, 43(3):153-156. [in Chinese].
24. Roskams T. Different types of liver progenitor cells and their niches. J Hepatol 2006, 45(1):1-4.
25. Zhou Y.M., Yin Z.F., Yang J.M., et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008, 14(4):632-635.
26. Lee T.Y., Lee S.S., Jung S.W., et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008, 103(7):1716-1720.
27. Shin H.R., Lee C.U., Park H.J., et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996, 25(5):933-940.
28. Donato F., Gelatti U., Tagger A., et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001, 12(10):959-964.
29. Shaib Y.H., El-Serag H.B., Davila J.A., et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005, 128(3):620-626.
30. Falchuk K.R., Lesser P.B., Galdabini J.J., et al. Cholangiocarcinoma as related to chronic intrahepatic cholangitis and hepatolithiasis. Case report and review of the literature. Am J Gastroenterol 1976, 66(1):57-61.
31. Nakanuma Y., Terada T., Tanaka Y., et al. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma. Virchows Arch A Pathol Anat Histopathol 1985, 406(1):45-58.
32. Kuroki T., Tajima Y., Kanematsu T. Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms. J Hepatobiliary Pancreat Surg 2005, 12(6):463-466.
33. Kawakami H., Kuwatani M., Onodera M., et al. Primary cholesterol hepatolithiasis associated with cholangiocellular carcinoma: a case report and literature review. Intern Med 2007, 46(15):1191-1196.
34. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155(4):323-331.
35. Torbenson M., Yeh M.M., Abraham S.C. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. Am J Surg Pathol 2007, 31(9):1410-1413.
36. Zhu A.X., Lauwers G.Y., Tanabe K.K. Cholangiocarcinoma in association with thorotrast exposure. J Hepatobiliary Pancreat Surg 2004, 11(6):430-433.
37. Sorensen H.T., Friis S., Olsen J.H., et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998, 28(4):921-925.
38. Welzel T.M., Graubard B.I., El-Serag H.B., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007, 5(10):1221-1228.
39. Sripa B., Kaewkes S., Sithithaworn P., et al. Liver fluke induces cholangiocarcinoma. PLoS Med 2007, 4(7):e201.
40. Thuwajit C., Thuwajit P., Uchida K., et al. Gene expression profiling defined pathways correlated with fibroblast cell proliferation induced by Opisthorchis viverrini excretory/secretory product. World J Gastroenterol 2006, 12(22):3585-3592.
41. Prakobwong S., Pinlaor S., Yongvanit P., et al. Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury. Int J Parasitol 2009, 39(7):825-835.
42. Sripa B., Kaewkes S. Localisation of parasite antigens and inflammatory responses in experimental opisthorchiasis. Int J Parasitol 2000, 30(6):735-740.
43. Jinawath N., Chamgramol Y., Furukawa Y., et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 2006, 44(4):1025-1038.
44. Yoon J.H., Werneburg N.W., Higuchi H., et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002, 62(22):6500-6505.
45. Fukase K., Ohtsuka H., Onogawa T., et al. Bile acids repress E-cadherin through the induction of Snail and increase cancer invasiveness in human hepatobiliary carcinoma. Cancer Sci 2008, 99(9):1785-1792.
46. Celli A., Que F.G., Gores G.J., et al. Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Am J Physiol 1998, 275(4 Pt 1):G749-G757.
47. Yamagiwa Y., Meng F., Patel T. Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci 2006, 78(21):2494-2502.
48. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41(1):5-15.
49. Okuda K., Nakanuma Y., Miyazaki M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol 2002, 17(10):1056-1063.
50. Sugawara H., Yasoshima M., Katayanagi K., et al. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 1998, 33(2):145-153.
51. Park J., Tadlock L., Gores G.J., et al. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999, 30(5):1128-1133.
52. Okada K., Shimizu Y., Nambu S., et al. Interleukin-6 functions as an autocrine growth factor in a colangiocarcinoma cell line. J Gastroenterol Hepatol 1994, 9(5):462-467.
53. Yokomuro S., Tsuji H., Lunz J.G., et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000, 32(1):26-35.
54. Isomoto H., Kobayashi S., Werneburg N.W., et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42(6):1329-1338.
55. Meng F., Yamagiwa Y., Ueno Y., et al. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 2006, 44(6):1055-1065.
56. Meng F., Wehbe-Janek H., Henson R., et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008, 27(3):378-386.
57. Wehbe H., Henson R., Meng F., et al. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 2006, 66(21):10517-10524.
58. Spirli C., Fabris L., Duner E., et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003, 124(3):737-753.
59. Gomez D., Morris-Stiff G., Toogood G.J., et al. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2008, 97(6):513-518.
60. Traub R.J., Macaranas J., Mungthin M., et al. A new PCR-based approach indicates the range of Clonorchis sinensis now extends to Central Thailand. PLoS Negl Trop Dis 2009, 3(1):e367.
61. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7(6):593-600.
62. Hezel A.F., Zhu A.X. Systemic therapy for biliary tract cancers. Oncologist 2008, 13(4):415-423.
63. Valle J., Harpreet W., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1278.
64. Colombo C., Crosignani A., Assaisso M., et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992, 16(4):924-930.
65. Pardi D.S., Loftus E.V., Kremers W.K., et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124(4):889-893.
66. Forsmo H.M., Horn A., Viste A., et al. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2008, 7(4):412-417.
67. Wu G.S., Wang J.H., Liu Z.R., et al. Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2002, 1(3):429-433.